Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin + Metformin FDC vs Monotherapy in Type 2 Diabetes (China)
CTR20130254Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Alogliptin + metformin fixed-dose combination, Alogliptin monotherapy and Metformin monotherapy (3 arms). Primary endpoint: Change in HbA1c from baseline at Week 26. Started Jan 2014; status: completed.
02
Drugs
alogliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20130254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130254.